Apyx Medical (NASDAQ:APYX) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Key Points

• Apyx Medical beat quarterly expectations, reporting an adjusted loss of $0.07 per share versus the projected $0.08 loss, while revenue reached $13.88 million compared with the $13.18 million consensus.
• Second-quarter revenue increased 22% to $13.9 million, driven by a 28% rise in surgical aesthetics sales. The company also began shipping its FDA-cleared AYON PowerLipo system and plans a broader launch in the third quarter.
• Profitability improved, but Apyx continued to use cash and faces tariff-related margin pressure. Management reaffirmed 2026 revenue guidance of $59 million to $60 million, including an expected decline in OEM revenue.

Apyx Medical (NASDAQ:APYX - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01, FiscalAI reports. The company had revenue of $13.88 million during the quarter, compared to analysts' expectations of $13.18 million. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.18%.

Here are the key takeaways from Apyx Medical's conference call:

• Second-quarter revenue rose 22% to $13.9 million, led by a 28% increase in surgical aesthetics sales to $12.4 million. Management attributed the growth to AYON adoption, higher international generator sales, and increased domestic single-use handpiece volume.
• AYON received FDA clearance for power-assisted liposuction, with initial shipments beginning in June and a broader commercial launch planned for the third quarter. Management said early surgeon feedback was “exceptional” and expects more than 95% of new AYON customers to include the PowerLipo attachment.
• Management highlighted clinical studies supporting Renuvion’s role in body contouring, including higher patient satisfaction and fewer abdominoplasty or revision procedures when combined with liposuction, while maintaining comparable complication rates.
• Profitability improved, with gross margin rising to 63.9%, operating loss narrowing to $1.8 million, and adjusted EBITDA loss improving to $0.7 million. However, operating cash use increased to $3.5 million, and the company ended the quarter with $27.6 million in cash.
• The company reaffirmed 2026 revenue guidance of $59 million to $60 million and expects OEM revenue to decline to approximately $5 million from $7.5 million in 2025. Tariffs are also pressuring margins, although potential tariff refunds are not included in current guidance.

Apyx Medical Price Performance

Shares of NASDAQ APYX traded down $0.11 during mid-day trading on Friday, reaching $4.05. The company's stock had a trading volume of 299,178 shares, compared to its average volume of 64,993. The stock has a 50-day moving average of $4.24 and a two-hundred day moving average of $3.94. The company has a debt-to-equity ratio of 2.68, a quick ratio of 4.79 and a current ratio of 5.80. The stock has a market capitalization of $169.74 million, a P/E ratio of -20.25 and a beta of 1.39. Apyx Medical has a 1-year low of $1.70 and a 1-year high of $5.08.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC purchased a new position in Apyx Medical during the third quarter worth approximately $28,000. Osaic Holdings Inc. purchased a new stake in Apyx Medical in the 2nd quarter valued at $50,000. Franklin Resources Inc. acquired a new stake in shares of Apyx Medical in the 3rd quarter worth $59,000. Hudson Bay Capital Management LP acquired a new stake in shares of Apyx Medical in the 4th quarter worth $73,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Apyx Medical during the 4th quarter worth $111,000. 55.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on APYX. Weiss Ratings reissued a "sell (d-)" rating on shares of Apyx Medical in a research note on Wednesday, June 24th. HC Wainwright began coverage on Apyx Medical in a report on Monday, July 13th. They issued a "buy" rating and a $7.00 price objective on the stock. Zacks Research upgraded Apyx Medical to a "hold" rating in a research note on Tuesday, July 14th. Finally, Wall Street Zen cut Apyx Medical from a "buy" rating to a "hold" rating in a report on Sunday, April 26th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $6.60.

Apyx Medical Company Profile

Apyx Medical NASDAQ: APYX is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company's product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source